Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing the Dose of Tafenoquine for Plasmodium Vivax Malaria in Southeast Asia
NCT04704999Phase 4Recruiting
- Sponsor
- University of Oxford
- Start
- Jul 2024
- Primary completion
- Oct 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial of tafenoquine in Plasmodium vivax malaria (3 arms), sponsored by University of Oxford. Primary endpoint: Microscopy positive P. vivax recurrence after radical treatment at 4 months. Started Jul 2024; status: recruiting.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT04704999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704999.